Member Info for crumbs

What is clear is a great deal of work has been going on here... and that pharma have been involved since at least 2015... seems as ever timelines have not quite worked out as expected however... things could be so advanced that a deal could drop at any moment.... as industry have been looking closely at these MaBs a lot longer than the RNS suggests ..... hopeful... also the MaBs and platform really do seem a very exciting addition to the pipeline.... all good!

And the question and answer after it quite revealing.... 2 companies involved both very serious about it hmmm

Interesting Lindy at 15.35 'antibody FG129 collaborations with industry to produce both a drug conjugate and a biospecific antibody so hopefully, in a few years we will be in the clinic' that was from 2016.... so promising that things are further a long now and action is close

Been posted previously but considering current news and plans.... worth a viewing :)

https://vimeo.com/155954442

Also liking the new website.... yes the timing is worth a cynical :) but at least it is here now.... think Cliff is listening

I suppose because that was always the idea... a US trial led by the number 1 KF in the best US clinics... such a huge endorsement and with data success such huge exposure in the biggest market in the world .... So I reckon it is not completely off the table and can only imagine the amount of work already gone into it but reality may well mean it never happens..... sad really..... We all know in an ideal world it would also be SCIB1 v2 using nano delivery too... but we are not currently in that position.... Anyways I have great hopes that the data will add validation to SCIB1 and the entire ImmunoBody platform... hopefully some SCIB2 CRUK progress towards clinic news is on its way too....

Yes, I agree.... I think if all 25 patients are able to be soon recruited in the UK then it will be UK only if however US approval comes and not all 25 are recruited then I assume the US arm could reappear ......

It could be an eventful AGM lol... I know the all-important first deal/s have not arrived with big money attached and the validation they would also bring but really a lot of IP enhancing progress has been made since last AGM and we have to be getting close to that mega sp shifting RNS surely! :)) ... 3 platforms multiple potential and clinically ready products capable of targetting tens of different cancers at varying disease stages....

Yeah great spot...doubt there will be a US arm now myself but relieved to see the trial online at last

https://www.proactiveinvestors.co.uk/companies/news/902103/antibody-collaboration-deal-for-scancell-902103.html

The sp has done better than I thought it would on today's RNS after all although positive once again it is a collaboration and not a money attached deal having said that on reading the Trinity report on it it does seem we could well be in for commercial activity on the glycan MAbs and AvidiMaB platform as we know this collaboration has not just come from nowhere, there is obviously industry interest and a great deal of competition between the big players in the MaB market a market predicted to be worth a whopping $138 billion by 2024 ...Roche(Genentech) is currently the biggest fish... I'm sure today's RNS will have been noted by all the MaB players who know it is not them who at this moment are looking as one of there rivals is at scancells tech :)... onwards!

yeah, maybe the 'sceond' collab has already arrived lol.....

ghost RNS we can all imagine what we want it to say

Yes.. they are getting the info from somewhere (scancell) lol... anyways the most important part is there is the first biter already... we have attracted the first fish of potentially many... and I think they do not want other big fishes to know they are now seriously looking at these MaBs and AvidiMaB... first in and all that :)

We might soon become a sweetshop, funds from which will go into moditope and ImmunoBody trials

'Scancell has started the partnering process, and has already formed a non-exclusive research collaboration with a leading antibody technology company so that the unnamed company can properly assess the antibodies and technology. The unique panel of glycan antibodies, and the ability of AvidiMabs to kill tumour cells could enhance the efficacy of many antibodies in oncology are likely to attract interest from other parties. So, we would not be surprised if other similar collaborations were formed ahead of a competitive, out-licensing discussions.

It should be noted that another company might have been reluctant to out-license such promising technologies, but sensibly Scancell is maintaining its focus on ImmunoBody and Moditope, and the funds received from any deal will be invested in the core technologies.

A summary of the characteristics of four of Scancell’s glycan antibodies is detailed in Exhibit 6. The data on these antibodies will be crucial for any licensor as they provide validation of the value of the technologies. Scancell has the option to out-license the antibodies, and the AvidiMab technology separately (and AvidiMab could be licensed to multiple parties on a non-exclusive basis), but in our opinion, it is most likely that the greatest return for the company will be achieved by partnering these assets together.'

'AvidiMab antibodies have specific modifications made to the Fc domain, which confer increased avidity and direct-killing ability with certain targets to the antibody at nanomolar concentration in vitro. Exhibit 4 provides an illustration of the effect of the AvidiMab on tumour cells.

Many antibodies depend on ADCC or ADCP to kill tumour cells, which rely on the necessary effector cells (T-cells and NK-cells) being active within a tumour. However, many tumours develop immunosuppressive microenvironments (become “cold” tumours) to evade detection by the immune system, and in these tumours an AvidiMab antibody should be more efficacious than a standard antibody.

It is important to note that AvidiMabs can kill tumour cells efficiently both directly and indirectly (via ADCC, ADCP or CDC; Exhibit 5). Theoretically, this technology can be applied to any antibody and not just to glycan antibodies and could be used to enhance their potency in oncology.'

Scancell has formed a non-exclusive collaboration with a leading antibody technology company, with a view to out-licensing its glycan antibodies and AvidiMab technology. Antibodies against glycans (carbohydrates on proteins or lipids) are difficult to make but have much potential in oncology as many are highly specific to tumour cells. AvidiMab enables an antibody to kill cancer cells directly, without mediation by other elements of the immune system. The potential of the glycan antibodies and AvidiMab platform, although they are still preclinical, is such that we believe Scancell could receive significant upfront and milestone payments, providing material non-dilutive funding for the core ImmunoBody and Moditope platforms.

https://www.trinitydelta.org/research-notes/a-sweet-source-of-financing/

haha...

Anyways as for who the mystery collaborator could be ... well I'm sure there are many candidates.... we know that Seattle Genetics has already been involved to some degree in the past with the development of the Glycan Mabs whilst they were with NUTAC .... but I'm wondering if it could be Genmab who also have a collab with BioNtech anyways scancells tech is not under any invisibility cloaks as far as the cutting edge companies in this industry are concerned ...things always going on that we only ever hear about when we do :)

Described as:

'
Pharmaceutical, therapeutic and medicinal preparations and substances to increase the avidity of antibodies for the treatment of cancer; compounds for the treatment of cancer.'

So we have 3 platforms now 3 products at clinical stage one close behind we have a novel TCR approach utilising moditope we have a number of glycan MaBs and we have a platform around that that can increase the avidity of MaBs.... surely at some point the deal/s arrive!!!

For interest.... the AvidiMaB trademark.... was only filed on Monday
https://trademarks.ipo.gov.uk/ipo-tmcase/page/Results/1/UK00003425430